SOLAR‐1 trial showed that fulvestrant plus alpelisib had statistically significant and PFS benefits on PIK3CA‐mutation, hormone receptor‐positive, HER2(−) advanced breast cancer [39, 149]. Here, NR4A1 is linked to breast cancer.